45 related articles for article (PubMed ID: 25301453)
1. The molecular mechanisms of a novel multi-kinase inhibitor ZLJ33 in suppressing pancreatic cancer growth.
Li Y; Tang K; Zhang L; Li C; Niu F; Zhou W; Yang H; Feng Z; Chen X
Cancer Lett; 2015 Jan; 356(2 Pt B):392-403. PubMed ID: 25301453
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Liao J; Hwang SH; Li H; Yang Y; Yang J; Wecksler AT; Liu JY; Hammock BD; Yang GY
Cancer Lett; 2016 Feb; 371(2):187-93. PubMed ID: 26683769
[TBL] [Abstract][Full Text] [Related]
3. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Gomes EG; Connelly SF; Summy JM
Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
[TBL] [Abstract][Full Text] [Related]
4. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
Yun SM; Jung KH; Lee H; Son MK; Seo JH; Yan HH; Park BH; Hong S; Hong SS
Cancer Lett; 2013 May; 331(2):250-61. PubMed ID: 23340175
[TBL] [Abstract][Full Text] [Related]
5. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells.
Tong WG; Ding XZ; Hennig R; Witt RC; Standop J; Pour PM; Adrian TE
Clin Cancer Res; 2002 Oct; 8(10):3232-42. PubMed ID: 12374694
[TBL] [Abstract][Full Text] [Related]
6. (-)-Epigallocatechin 3-gallate inhibits invasion by inducing the expression of Raf kinase inhibitor protein in AsPC‑1 human pancreatic adenocarcinoma cells through the modulation of histone deacetylase activity.
Kim SO; Kim MR
Int J Oncol; 2013 Jan; 42(1):349-58. PubMed ID: 23135610
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic tumor mass in a xenograft mouse model is decreased by treatment with therapeutic stem cells following introduction of therapeutic genes.
Kim DJ; Yi BR; Lee HR; Kim SU; Choi KC
Oncol Rep; 2013 Sep; 30(3):1129-36. PubMed ID: 23807450
[TBL] [Abstract][Full Text] [Related]
8. Beta-adrenoceptor action on pancreatic cancer cell proliferation and tumor growth in mice.
Lin X; Luo K; Lv Z; Huang J
Hepatogastroenterology; 2012; 59(114):584-8. PubMed ID: 22353526
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of β-catenin inhibitors and sorafenib in hepatoma cells.
Muche S; Kirschnick M; Schwarz M; Braeuning A
Anticancer Res; 2014 Sep; 34(9):4677-83. PubMed ID: 25202044
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
11. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
12. Anti-cancer effect of HS-345, a new tropomyosin-related kinase A inhibitor, on human pancreatic cancer.
Seo JH; Jung KH; Son MK; Yan HH; Ryu YL; Kim J; Lee JK; Hong S; Hong SS
Cancer Lett; 2013 Sep; 338(2):271-81. PubMed ID: 23587795
[TBL] [Abstract][Full Text] [Related]
13. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
14. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis.
Tanaka S; Pero SC; Taguchi K; Shimada M; Mori M; Krag DN; Arii S
J Natl Cancer Inst; 2006 Apr; 98(7):491-8. PubMed ID: 16595785
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
16. B7-H4 enhances oncogenicity and inhibits apoptosis in pancreatic cancer cells.
Qian Y; Hong B; Shen L; Wu Z; Yao H; Zhang L
Cell Tissue Res; 2013 Jul; 353(1):139-51. PubMed ID: 23660627
[TBL] [Abstract][Full Text] [Related]
17. Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway.
Shin-Kang S; Ramsauer VP; Lightner J; Chakraborty K; Stone W; Campbell S; Reddy SA; Krishnan K
Free Radic Biol Med; 2011 Sep; 51(6):1164-74. PubMed ID: 21723941
[TBL] [Abstract][Full Text] [Related]
18. VEGFR, RET, and RAF/MEK/ERK pathway take part in the inhibition of osteosarcoma MG63 cells with sorafenib treatment.
Mei J; Zhu X; Wang Z; Wang Z
Cell Biochem Biophys; 2014 May; 69(1):151-6. PubMed ID: 24375110
[TBL] [Abstract][Full Text] [Related]
19. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
[TBL] [Abstract][Full Text] [Related]
20. [Effect of NK4 gene transfection on tumor growth of human pancreatic cancer xenograft in nude mice].
Lai RX; Zhang SN; Nakamura T; Yuan SZ
Ai Zheng; 2005 Oct; 24(10):1191-5. PubMed ID: 16219131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
